sodium picosulfate monohydrate: clinical use

Prescribing considerations

• Confirm that dietary measures or bulk-forming approaches have been insufficient before selecting a stimulant laxative for self-limited constipation.
• Investigate persistent or recurrent constipation rather than supporting continuous stimulant-laxative use.
• Consider dehydration risk carefully in older people and those with renal impairment or existing fluid loss.
• Assess misuse risk, including use associated with eating disorders; sodium picosulfate does not cause fat loss.

Contraindications and cautions

• Ileus or intestinal obstruction
• Severe painful or febrile acute abdominal conditions, particularly with nausea or vomiting
• Acute inflammatory bowel disease
• Severe dehydration
• Hypersensitivity to sodium picosulfate or formulation components
• Product-specific hereditary incompatibility with an excipient

Monitoring

• Routine laboratory monitoring is not usually required for occasional use.
• Assess hydration and electrolytes when there is excessive use, significant diarrhoea or vulnerability to fluid loss.
• Review the underlying cause if laxatives are repeatedly required.

Clinical pharmacology

Sodium picosulfate is a minimally absorbed triarylmethane prodrug. Colonic bacteria cleave it to BHPM, which stimulates colonic and rectal mucosa, increases peristalsis and promotes water and electrolyte accumulation in the lumen.

Formulation and product differences

• The selected products are oral solutions, but their licensed age groups differ: the Adult Pico product is restricted to adults, whereas the Twelve Plus product includes people over 12 years.
• Both selected formulations contain ethanol and the preservatives methyl parahydroxybenzoate and propyl parahydroxybenzoate; consider their relevance in pregnancy, breastfeeding, liver disease, epilepsy, alcohol dependence or previous excipient hypersensitivity.

Oral solution

Route: Oral

Strengths: 5 mg/5 mL